Investors
Why Invest in DomainOne Therapeutics?
The impacts of AKI and CKD in the US and around the globe are huge– approximately 22% of all hospitalized patients experience AKI while the global prevalence of CKD is approaching an estimated 1 billion people. Both conditions significantly increase patient mortality, and risk of developing other chronic conditions or progressing to renal failure. Current treatments only manage symptoms rather than addressing the root cause, and the only treatment option for patients with severe kidney impairment is kidney transplant or permanent dialysis. DomainOne Therapeutics’ novel TSP-1-targeted approach offers a highly specific, first-in-class solution to stopping fibrosis at its source and provide much needed relief for these patients with critical unmet need.
Backed by Orange Grove Bio, and built on groundbreaking research from the University of Alabama and Southern Research Institute, DomainOne Therapeutics is positioned to advance our novel therapeutic treatments for AKI and CKD and expand into the broader field of TGF-β-driven diseases.
Investment Highlights
First-in-Class TSP-1 Antagonists: Modulating TGF-β activation at disease sites to prevent fibrosis progression while minimizing systemic toxicity.
Targeting a Large, Unmet Market: Fibrosis-related diseases represent multi-billion-dollar opportunities across kidney, liver, lung, and heart indications.
Strong Scientific Foundation: Built on academic discoveries from the University of Alabama and Southern Research, led by Dr. Joanne Murphy-Ullrich, a leading expert in TSP-1 and TGF-β biology.
Advancing Toward Clinical Development: Preclinical data demonstrates strong efficacy in multiple fibrosis models, supporting a clear regulatory path forward.
Recent News
Read about our latest developments, including funding rounds, partnership announcements, and progress in our pipeline.
